Treatment with finasteride and prostate cancer survival

References

• Imamoto T, Suzuki H, Utsumi T, Endo T, Takano M, Yano M, et al. Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol 2009;5:1005–13.
   Google Scholar
• Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study. Eur Urol 2008;53:106–11.
   Google Scholar
• Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.
   PubMed Web of Science ®Google Scholar
• Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol 2004;172:1314–17.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192–202.
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Tammela TL, Maattanen L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 2009;101:843–8.
   PubMed Web of Science ®Google Scholar
• Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006;53:441–9.
   PubMed Web of Science ®Google Scholar
• Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University Prescription Database. Clin Epidemiol 2010;2:273–9.
   PubMedGoogle Scholar
• Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997;44:445–8.
   PubMed Web of Science ®Google Scholar
• World Health Organization. ATC classification index with DDDs. Geneva: WHO; 2003.
   Google Scholar
• Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry – history, content, quality and use. Dan Med Bull 1997;44:535–9.
   PubMed Web of Science ®Google Scholar
• Juel K. Registration of cause of death in Denmark. Ugeskr Laeger 1998;160:5019.
   Google Scholar
• Mabeck CE, Wichmann B. Causes of death and death certificates. An evaluation of the diagnosis in 373 death certificates. Ugeskr Laeger 1980;142:257–61.
   PubMedGoogle Scholar
• Asnaes S, Ostergaard K. Reliability of death certificates. An autopsy study. Ugeskr Laeger 1980;142:265–6.
   Google Scholar
• Brasso K, Friis S, Juel K, Jorgensen T, Iversen P. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. J Urol 1999;161:524–8.
   PubMed Web of Science ®Google Scholar
• Benning CM, Kyprianou N. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action. Cancer Res 2002;62:597–602.
   PubMed Web of Science ®Google Scholar
• Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, et al. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 2007;178:2176–80.
   PubMedGoogle Scholar
• Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3 009 258 men. Eur Urol 2011;60:691–8.
   PubMed Web of Science ®Google Scholar
• Jonler M, Eddy B, Poulsen J. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Scand J Urol Nephrol 2005;39:214–18.
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Tammela TL, Maattanen L, Hakama M, Auvinen A. Prostate cancer risk among users of finasteride and alpha-blockers – a population based case–control study. Eur J Cancer 2007;43:775–81.
   PubMed Web of Science ®Google Scholar
• Lebdai S, Bigot P, Azzouzi AR. High-grade prostate cancer and finasteride. BJU Int 2010;105:456–9.
   Google Scholar